JP Morgan Chase’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-134
| Closed | -$1.53K | – | 8109 |
|
|
2023
Q4 | $1.53K | Hold |
134
| – | – | ﹤0.01% | 6766 |
|
|
2023
Q3 | $557 | Sell |
134
-2
| -1% | -$15 | ﹤0.01% | 6713 |
|
|
2023
Q2 | $968 | Sell |
136
-8
| -6% | -$55 | ﹤0.01% | 6461 |
|
|
2023
Q1 | $1K | Buy |
144
+8
| +6% | +$67 | ﹤0.01% | 6589 |
|
|
2022
Q4 | $1K | Sell |
136
-114
| -46% | -$960 | ﹤0.01% | 6480 |
|
|
2022
Q3 | $2K | Buy |
250
+71
| +40% | +$1.32K | ﹤0.01% | 6283 |
|
|
2022
Q2 | $3K | Sell |
179
-19,856
| -99% | -$514K | ﹤0.01% | 6259 |
|
|
2022
Q1 | $996K | Sell |
20,035
-409
| -2% | -$21.2K | ﹤0.01% | 4267 |
|
|
2021
Q4 | $1.54M | Sell |
20,444
-985
| -5% | -$67.2K | ﹤0.01% | 4039 |
|
|
2021
Q3 | $1.69M | Sell |
21,429
-1,403
| -6% | -$141K | ﹤0.01% | 3920 |
|
|
2021
Q2 | $3.17M | Sell |
22,832
-1,177
| -5% | -$225K | ﹤0.01% | 3434 |
|
|
2021
Q1 | $5.02M | Buy |
24,009
+15,499
| +182% | +$3.11M | ﹤0.01% | 2971 |
|
|
2020
Q4 | $1.41M | Buy |
8,510
+8,116
| +2,060% | +$1.25M | ﹤0.01% | 3728 |
|
|
2020
Q3 | $63K | Sell |
394
-393
| -50% | -$56.7K | ﹤0.01% | 4878 |
|
|
2020
Q2 | $130K | Buy |
787
+552
| +235% | +$86.1K | ﹤0.01% | 4462 |
|
|
2020
Q1 | $27K | Sell |
235
-3
| -1% | -$422 | ﹤0.01% | 4886 |
|
|
2019
Q4 | $35K | Hold |
238
| – | – | ﹤0.01% | 5226 |
|
|
2019
Q3 | $32K | Buy |
238
+75
| +46% | +$10.5K | ﹤0.01% | 5309 |
|
|
2019
Q2 | $20K | Buy |
163
+101
| +163% | +$11.7K | ﹤0.01% | 5447 |
|
|
2019
Q1 | $6K | Buy |
+62
| New | +$8.15K | ﹤0.01% | 5607 |
|
JP Morgan Chase's HARP Position: Q1 2024 in Review
JP Morgan Chase sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 134 shares — an estimated $1.53K sold.
JP Morgan Chase first reported a position in HARP in Q1 2019 and held it in 20 quarters. The position peaked at $5.02M in Q1 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- JP Morgan Chase reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- JP Morgan Chase sold 134 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.53K.
- JP Morgan Chase first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 20 quarters.
- JP Morgan Chase's Harpoon Therapeutics, Inc. Common Stock position peaked at $5.02M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.